<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>317</serviceExecutionTime><Drug id="4366"><DrugName>SC-53116</DrugName><DrugSynonyms><Name><Value>SC-53116</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>141196-99-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18362">GD Searle &amp; Co</CompanyOriginator><CompaniesSecondary><Company id="18362">GD Searle &amp; Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="4366" type="Drug"><TargetEntity id="174625" type="siDrug">SC-53116</TargetEntity></SourceEntity><SourceEntity id="18362" type="Company"><TargetEntity id="5001166864" type="organizationId">GD Searle &amp; Co</TargetEntity></SourceEntity><SourceEntity id="440" type="Action"><TargetEntity id="229" type="Mechanism">5-HT4 Agonists</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="376">Gastric motility disorder</Indication></IndicationsSecondary><ActionsPrimary><Action id="440">5-HT 4 receptor agonist</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-09-02T05:30:23.000Z</LastModificationDate><ChangeDateLast>2003-04-17T11:12:03.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="4366" linkType="Drug"&gt;SC-53116&lt;/ulink&gt; is a selective 5-HT 4 agonist that was being developed by &lt;ulink linkID="18362" linkType="Company"&gt;Searle&lt;/ulink&gt; as a potential treatment for gastric motility disorder. The compound only reached the preclinical stages of development before being discontinued and is now being used as a research tool to characterize 5-HT 4 receptors.&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18362">GD Searle &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="376">Gastric motility disorder</Indication></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18362">GD Searle &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="376">Gastric motility disorder</Indication></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00026"><Name>5-HT 4 receptor</Name><SwissprotNumbers><Swissprot>O70528</Swissprot><Swissprot>P97288</Swissprot><Swissprot>Q13639</Swissprot><Swissprot>Q29006</Swissprot><Swissprot>Q62758</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>COc1cc(c(cc1C(=O)NC[C@@H]2CCN3[C@H]2CCC3)Cl)N</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>